Erin Macrae is an Oncology physician affiliated with Columbus Oncology and Hematology Associates. OpenAlex indexes 40 publications with 1,678 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
810 Jasonway Ave Ste A
Columbus, OH 432144359
Telephone
614-442-3130Provider last certified this registry record 12 Aug 2024.
Clinical trials
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Eisai Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
53.9%Other antiemetics48.2%Fosaprepitant100%Part B, office-administered≥25 patientsSerotonin-3 Receptor Antagonist5%Palonosetron hcl97%Ondansetron Hcl2%Ondansetron Odt1%Part D + Part B<11 patients+ 5 more classes in this area
Cancer & immunology
36.7%PD-1 inhibitor32.5%Pembrolizumab100%Part B, office-administered≥11 patientsNucleoside Metabolic Inhibitor2.4%Fluorouracil100%Part B, office-administered≥15 patients+ 5 more classes in this area
Sensory organs
6.9%Corticosteroid6.8%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B<11 patientsFluoroquinolone Antibacterial0.1%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Elena Christofides, MD, FACE
Columbus Oncology and Hematology Associates
Peter Kourlas, MD
Columbus Oncology and Hematology Associates
Jarred Burkart, MD
Columbus Oncology and Hematology Associates
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”